Pharmacokinetics of an oral solution of the microemulsion formulation of cyclosporine in maintenance pediatric liver transplant recipients

Transplantation

Volumn 63, Issue 12, 1997, Pages 1762-1767

  Dunn, Stephen ^a   Cooney, Gerard ^a   Sommerauer, John ^b   Lindsay, Christine ^b   McDiarmid, Sue ^c   Wong, Robert L ^d   Chang, Cheng Tao ^e   Smith, Harold T ^d   Choc Jr , M Gerry ^d  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c UCLA MEDICAL CENTER   (United States)

^d Sandoz Pharma Ltd   (Switzerland)

^e Ohneida Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CREATININE; CYCLOSPORIN; DRUG METABOLITE; STEROID;

ADOLESCENT; AREA UNDER THE CURVE; ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG FORMULATION; DRUG METABOLISM; FLUORESCENCE POLARIZATION IMMUNOASSAY; GRAFT REJECTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER FUNCTION; LIVER TRANSPLANTATION; MICROEMULSION; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ABSORPTION; ADMINISTRATION, ORAL; ADOLESCENT; AGE FACTORS; BIOLOGICAL AVAILABILITY; CHILD; CHILD, PRESCHOOL; CROSS-OVER STUDIES; CYCLOSPORINE; DRUG DELIVERY SYSTEMS; EMULSIONS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; LIVER TRANSPLANTATION; MALE;

EID: 0030996545     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199706270-00010     Document Type: Article

References (17)

1. Kovarik JM, Mueller EA, van Bree JB, et al. Cyclosporine pharmacokinetics and variability from a microemulsion formulation - a multicenter investigation in kidney transplant patients. Transplantation 1994; 58: 658.
2. Kahan BD, Welsh M, Schoenberg L, et al. Variable oral absorption of cyclosporine: a biopharmaceutical risk factor for chronic renal allograft rejection. Transplantation 1996; 62: 599.
3. Whitington PF, Alonso EM, Piper JB. Pediatric liver transplantation. Semin Liver Dis 1994; 14: 303.
4. Whitington PF, Emond JC, Whitington SH, Broelsch CE, Baker AT. Small-bowel length and the dose of cyclosporine in children after liver transplantation. N Engl J Med 1990; 322: 733.
5. Dunn SP, Cooney GF, Kulinsky AV, Falkenstein K, Kaiser B, Goldsmith B. Cyclosporine pharmacokinetics in pediatric liver transplant recipients: utility of the monoclonal radioimmunoassay single point blood concentration. Transplant Proc 1994; 26: 151.
6. Klare B, Walter JV, Hahn H, Emmrich P, Land W. Cyclosporin in renal transplantation in children. Lancet 1984; 2: 692.
7. Ptachcinski RJ, Burckart GJ, Rosenthal JT, et al. Cyclosporine pharmacokinetics in children following cadaveric renal transplantation. Transplant Proc 1986; 18: 766.
8. Burckart G, Starzl T, Williams L, et al. Cyclosporine monitoring and pharmacokinetics in pediatric liver transplant patients. Transplant Proc 1985; 17: 1172.
9. Vonderscher J, Meinzer A. Rationale for the development of Sandimmune Neoral. Transplant Proc 1994; 26: 2925.
10. Dunn OJ, Clark V. Correlation coefficients measured on the same individuals. Am Stat Assoc J 1969; 64: 366.
11. Koch GG. The use of non-parametric methods in the statistical analysis of the two-period change-over design. Biometrics 1972; 28: 577.
12. Atkison PR, Grant DR, Williams SE, Howard J, Wall WJ, Stiller CR. Sandimmune Neoral in paediatric liver transplant recipients with malabsorption of cyclosporin A. Transplant Proc 1994; 26: 2953.
13. Superina RA, Strong DK, Acal LA, DeLuca E. Relative bioavailability of Sandimmune and Sandimmune Neoral in pediatric liver recipients. Transplant Proc 1994; 26: 2979.
14. Dunn SP, Cooney GF, Kulinsky A, et al. Absorption characteristics of a microemulsion formulation of cyclosporine in de novo pediatric liver transplant recipients. Transplantation 1995; 60: 1438.
15. Holmberg C, Laine J, Jalanko H, Leijala M, Hoppu K. Conversion from cyclosporine to Neoral in pediatric recipients for kidney, liver, and heart transplantation. Transplant Proc 1996; 28: 2262.
16. Grant D, Rochon R, Levy G, and the Ontario Liver Transplant Study Group. Comparison of the long-term tolerability, pharmacodynamics, and safety of Sandimmune and Neoral in liver transplant recipients. Transplant Proc 1996; 28: 2232.
17. Pescovitz MD, Barone G, Choc MG Jr, et al. Safety and tolerability of cyclosporine microemulsion versus cyclosporine: two-year data in primary renal allograft recipients. A report of the Neoral Study Group. Transplantation 1997; 63: 778.